Suicide prevention and postvention in hospitals in Japan: current status and perspectives.

Suicide prevention and postvention in hospitals in Japan: current status and perspectives.
复制标题

日本医院的自杀预防和预防:现状和前景。

DOI:
10.1111/pcn.13015
复制
发表时间:
2020
期刊:
Psychiatry Clin Neurisci
影响因子:
--
通讯作者:
Otsuka K
Otsuka K
中科院分区:
--
文献类型:
--
作者:
Inoue K;Kawanishi C;Narita K;Cho Y;Otsuka K

文献摘要

相似文献

自20世纪90年代以来,住院患者自杀一直被列为美国医院常见的严重事件。[1]在日本,2005年,日本优质医疗保健理事会(JCQHC)的患者安全促进(PSP)委员会首次进行了一项调查,以揭示日本住院患者自杀的情况。[2]30%(170/575)的参与医院在过去3年内报告了347例住院自杀事件。Inoue博士报告了Yoshitomi Pharmaceutical Industries的个人费用以及提交工作之外的科学研究补助金的赠款。Cho教授报告了Shionogi的个人费用、Eli Lilly Japan的个人费用、Kyowa Kirin的个人费用、Pfizer Japan的个人费用、Otsuka Pharmaceutical的赠款和个人费用、Meiji Seika Pharma的个人费用、Mitsubishi田边Pharma的个人费用、Sumitomo Dainippon Pharma的个人费用、Astellas Pharma的个人费用以及MSD在提交的工作之外的个人费用。精神病学和临床神经科学的版权是Wiley-Blackwell的财产,未经版权保持器的明确书面许可,其内容不得复制或通过电子邮件发送到多个网站或发布到列表服务器。但是,用户可以打印,下载或电子邮件的文章供个人使用。本摘要可能会被删节。对副本的准确性不作任何保证。用户应参考材料的原始出版版本以获取完整摘要。版权适用于所有摘要。
Inpatient suicide has been listed as a common severe incident in hospitals in the USA since the 1990s.[1] In Japan, the Patient Safety Promotion (PSP) Committee of the Japan Council for Quality Health Care (JCQHC) first conducted a survey to reveal the situation regarding inpatient suicides in Japan in 2005.[2] Thirty percent (170/575) of the participating hospitals reported a total of 347 inpatient suicides within the previous 3 years. Disclosure statement Dr Inoue reports personal fees from Yoshitomi Pharmaceutical Industries and grants from Grant-in-Aid for Scientific Research outside the submitted work. Professor Cho reports personal fees from Shionogi, personal fees from Eli Lilly Japan, personal fees from Kyowa Kirin, personal fees from Pfizer Japan, grants and personal fees from Otsuka Pharmaceutical, personal fees from Meiji Seika Pharma, personal fees from Mitsubishi Tanabe Pharma, personal fees from Sumitomo Dainippon Pharma, personal fees from Astellas Pharma, and personal fees from MSD outside the submitted work.[Extracted from the article]Copyright of Psychiatry & Clinical Neurosciences is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. Copyright applies to all Abstracts.